spacer
home > ict > autumn 2009 > endogenous insulin delivery on demand
PUBLICATIONS
International Clinical Trials

Endogenous Insulin Delivery on Demand

 

The autoimmune destruction of pancreatic beta islet cells in type 1 diabetes severely disrupts normal glucose metabolism and causes a chronic and incurable life threatening disease. Treatment with exogenous insulin is life-saving, but requires a complicated daily regimen of multiple injections and blood glucose monitoring. Insulin dosing is adjusted to prevent fluctuations of blood glucose levels to limit episodes of hyperglycaemia. Failure to maintain euglycaemia results in micro- and macrovascular disease and the late complications of diabetes such as nephropathy, retinopathy, hypertension, diabetic ulcers, neuropathy and cardiomyopathy.

The American Diabetes Association recommends a target glycated haemoglobin level of less than seven per cent (HbA1c) as a reflection of consistent euglycemia such that haemoglobin is not abnormally glycated consequent to frequent or prolonged periods of hyperglycaemia. A normal HbA1c is a reliable surrogate predictor of reduced risk of the long term complications of diabetes (1).

While intensive insulin therapy has been encouraged primarily to avoid the delayed complications of diabetes, an intensive insulin regimen in many cases increases the occurrence of hypoglycaemic events (2). The Diabetes Control and Complications Trial reveals that most of the episodes of hypoglycaemia occur when the patient is asleep at night (3). Of great concern too is that, with chronic diabetes, patients frequently become unaware of impending hypoglycaemia, even when they are awake. New methods and devices for insulin delivery and monitoring continue to be developed to improve the management of blood glucose levels. Nevertheless, episodic hypoglycaemia and hypoglycaemic unawareness remain life-threatening risks for a significant number of patients with type 1 diabetes who follow medical advice to normalise their HbA1c level.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Paul L J Tan is Chief Executive Officer of Living Cell Technologies Limited. Prior to this he was Chief Executive Officer of CenTec Ltd, Australia and founding Deputy Director and Head of Health Division at Genesis Research & Development Corporation Limited, New Zealand. He has developed therapeutic products for early Phase I/II clinical trials in the US, the UK, New Zealand, Australia, Brazil and The Philippines. He was Associate Professor in immunology at the University of Auckland and a physician rheumatologist.

Kathleen Durbin is Clinical Trials Officer of Living Cell Technologies Limited. A PhD graduate in Chemistry from Edinburgh, she has many years experience managing clinical trials. She has worked with international clinical research organisations in the UK and France, including Quintiles in Scotland, and more recently in the NZ biotech sector since moving to New Zealand.

Robert Elliott is Medical Director of Living Cell Technologies Limited. A medical graduate from Adelaide University, he was the Foundation Professor, Director of Paediatrics at the University of Auckland. Robert co-founded LCT. He is an Emeritus Professor of Child Health Research, Professor of Paediatrics and a world leader in diabetes and autoimmune related research. In 1999 he was awarded a Companion of the New Zealand Order of Merit for services to the community.

spacer
Paul LJ Tan
spacer
spacer
spacer
Kathleen Durbin
spacer
spacer
spacer
Robert Elliott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up Tailored upstream development from a single source reduces time to clinic by 20 percent Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement